The value of biopharma deals in 2021 rose above the prior year’s record by about 8%, thanks to an increasing number of high-money transactions. Mergers and acquisitions, however, fell 32% below 2020 as the industry gravitated more toward financings.
While the $118.3 billion raised by biopharma companies in 2021 through public and private transactions is 12% lower than the amount raised the prior year, it still represents an impressive financings record, led primarily by IPOs and venture capital rounds.
RSS
